Doherty P - Search Results

1

Drug repositioning and repurposing for Alzheimer disease.

Ballard C, Aarsland D, Cummings J, O'Brien J, Mills R, Molinuevo JL, Fladby T, Williams G, Doherty P, Corbett A, Sultana J. Ballard C, et al. Among authors: doherty p. Nat Rev Neurol. 2020 Dec;16(12):661-673. doi: 10.1038/s41582-020-0397-4. Epub 2020 Sep 16. Nat Rev Neurol. 2020. PMID: 32939050 Free PMC article. Review.

2

Drug repurposing for Alzheimer's disease based on transcriptional profiling of human iPSC-derived cortical neurons.

Williams G, Gatt A, Clarke E, Corcoran J, Doherty P, Chambers D, Ballard C. Williams G, et al. Among authors: doherty p. Transl Psychiatry. 2019 Sep 6;9(1):220. doi: 10.1038/s41398-019-0555-x. Transl Psychiatry. 2019. PMID: 31492831 Free PMC article.

3

Alzheimer's Disease Progression in the 5×FAD Mouse Captured with a Multiplex Gene Expression Array.

Gatt A, Whitfield DR, Ballard C, Doherty P, Williams G. Gatt A, et al. Among authors: doherty p. J Alzheimers Dis. 2019;72(4):1177-1191. doi: 10.3233/JAD-190805. J Alzheimers Dis. 2019. PMID: 31683485

4

Transcription-based drug repurposing for COVID-19.

Killick R, Ballard C, Doherty P, Williams G. Killick R, et al. Among authors: doherty p. Virus Res. 2020 Dec;290:198176. doi: 10.1016/j.virusres.2020.198176. Epub 2020 Sep 25. Virus Res. 2020. PMID: 32987033 Free PMC article.

5

Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats.

Fletcher EJR, Jamieson AD, Williams G, Doherty P, Duty S. Fletcher EJR, et al. Among authors: doherty p. Sci Rep. 2019 Jun 6;9(1):8336. doi: 10.1038/s41598-019-44803-1. Sci Rep. 2019. PMID: 31171821 Free PMC article.

6

Inter-residue distances derived from fold contact propensities correlate with evolutionary substitution costs.

Williams G, Doherty P. Williams G, et al. Among authors: doherty p. BMC Bioinformatics. 2004 Oct 18;5:153. doi: 10.1186/1471-2105-5-153. BMC Bioinformatics. 2004. PMID: 15491497 Free PMC article.

7

2-Linoleoylglycerol Is a Partial Agonist of the Human Cannabinoid Type 1 Receptor that Can Suppress 2-Arachidonolyglycerol and Anandamide Activity.

Lu L, Williams G, Doherty P. Lu L, et al. Among authors: doherty p. Cannabis Cannabinoid Res. 2019 Dec 9;4(4):231-239. doi: 10.1089/can.2019.0030. eCollection 2019. Cannabis Cannabinoid Res. 2019. PMID: 31872059 Free PMC article.

8

Tandem repeat peptide strategy for the design of neurotrophic factor mimetics.

Molina-Holgado F, Doherty P, Williams G. Molina-Holgado F, et al. Among authors: doherty p. CNS Neurol Disord Drug Targets. 2008 Feb;7(1):110-9. doi: 10.2174/187152708783885200. CNS Neurol Disord Drug Targets. 2008. PMID: 18289037 Review.

9

No transcriptional evidence for active Na_v channels in two classes of cancer cell.

Hompoonsup S, Chambers D, Doherty P, Williams G. Hompoonsup S, et al. Among authors: doherty p. Channels (Austin). 2019 Dec;13(1):311-320. doi: 10.1080/19336950.2019.1644858. Channels (Austin). 2019. PMID: 31329011 Free PMC article.

10

Dimeric versions of two short N-cadherin binding motifs (HAVDI and INPISG) function as N-cadherin agonists.

Williams G, Williams EJ, Doherty P. Williams G, et al. Among authors: doherty p. J Biol Chem. 2002 Feb 8;277(6):4361-7. doi: 10.1074/jbc.M109185200. Epub 2001 Nov 28. J Biol Chem. 2002. PMID: 11726665 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,060 results

Search Page